My guess - biggest off label after child Gvhd approval will probably be adult gvhd since diseases are similar, and MSB has good results for both.
I say this as I guess off label use will occur in the same hospitals the doctors and staff are trained, which are specialist cancer hospitals and so have more gvhd than say crohns or ards patients.
I can't imagine hospitals that have no sales team present , requesting training and large scale use for essentialy only off label.
My guess - biggest off label after child Gvhd approval will...
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.05 |
Change
0.020(1.95%) |
Mkt cap ! $1.198B | |||
| Open | High | Low | Value | Volume |
| $1.02 | $1.07 | $1.02 | $3.019M | 2.903M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 13 | 61051 | $1.04 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.05 | 30483 | 11 |
View Market Depth
| Last trade - 11.22am 07/06/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.05 |
Change
0.020 ( 1.89 %) |
||||
| Open | High | Low | Volume | ||
| $1.02 | $1.07 | $1.02 | 438660 | ||
| Last updated 11.43am 07/06/2024 ? | |||||
| MSB (ASX) Chart |